A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia

txt4TKI: An Innovative Mobile Intervention to Improve Tyrosine Kinase Inhibitor Management Among Chronic Myeloid Leukemia Patients

This trial studies the feasibility and acceptability of a mobile intervention called txt4TKI for the improvement of tyrosine kinase inhibitor management in patients with chronic myeloid leukemia. Tyrosine kinase inhibitors (TKI) are associated with numerous potential side effects, including a decrease in bone marrow activity (myelosuppression), nausea, diarrhea, fatigue, and soft-tissue swelling (edema), especially in the face and lower legs, which are the primary reasons for patients to discontinue TKI medication. Using a mobile text messaging (TXT) intervention that emphasizes the importance of TKI compliance may improve TKI adherence in patients with chronic myeloid leukemia.

Inclusion Criteria:

• PHASE 1: Patients diagnosed with chronic myeloid leukemia
• PHASE 1: Initiated tyrosine kinase inhibitors therapy for a year
• PHASE 1: Able to read and understand English
• PHASE 1: Able to provide informed consent
• PHASE 1: Have a mobile phone with TXT capability
• PHASE 1: Know how to use TXT
• PHASE 2: Patients diagnosed with chronic myeloid leukemia in the chronic phase
• PHASE 2: Starting tyrosine kinase inhibitors therapy or has been on tyrosine kinase inhibitors with anticipation of at least 6 month duration of use
• PHASE 2: Able to read and understand English
• PHASE 2: Able to provide informed consent
• PHASE 2: Have a mobile device with TXT capability
• PHASE 2: Willing to use a wireless pill bottle during study for 6 months
• PHASE 2: Know or willing to learn how to use TXT

Exclusion Criteria:

• Cognitive impaired document in the electronic medical record (EMR)